PMID- 21626008
OWN - NLM
STAT- MEDLINE
DCOM- 20110905
LR  - 20211020
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Print)
IS  - 0171-5216 (Linking)
VI  - 137
IP  - 8
DP  - 2011 Aug
TI  - Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic 
      carcinoma, a rare lung malignancy.
PG  - 1203-11
LID - 10.1007/s00432-011-0986-0 [doi]
AB  - BACKGROUND: Pulmonary pleomorphic carcinoma (PPC) is a rare type of lung cancer 
      characterized by the poor response to conventional chemotherapy and subsequent 
      disappointing outcomes. Therefore, it is paramount to delineate the molecular 
      characteristics of this disease entity. METHODS: In this study, we 
      retrospectively examined the surgical specimens of 61 patients who underwent lung 
      surgery. Mutational or gene amplification statuses of epidermal growth factor 
      receptor (EGFR), k-ras, c-kit, c-met, and fibroblast growth factor receptor 
      (FGFR) were examined using genomic DNA sequencing, real-time PCR and/or 
      fluorescence in situ hybridization (FISH). RESULTS: The median age was 61 years, 
      and 50 patients were men and 11 were women. In the histologic review of 
      epithelial component, adenocarcinoma were in 44 cases (72%), squamous cell 
      carcinoma in 15 (25%) and large cell carcinoma in 2 patients (3%). Overall, 30 
      cases (49%) had any molecular alterations. Nine patients (15%) possessed EGFR 
      deletion in exon 19 (n = 8) or L858R mutations in exon 21 (n = 1), while 3 other 
      cases having atypical EGFR mutations. Six patients (9.8%) had k-ras mutations in 
      exon 12, and 3 had c-kit mutations. High gene copy number of c-met was found in 
      11 patients (18.0%) and that of FGFR was in 6 patients (9.8%). No significant 
      relationships were identified among the occurrence and type of mutations and 
      patient survival or any other clinicopathological variables. CONCLUSIONS: Given 
      the diverse repertoire of mutational profiles observed in PPC samples, clinical 
      trials based on accurate cancer-genotyping should be considered as a legitimate 
      treatment scheme for this rare disease entity in the future.
FAU - Lee, Soohyeon
AU  - Lee S
AD  - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, 50 Irwon-dong Gangnam-gu, Seoul 
      135-710, Korea.
FAU - Kim, Youngwook
AU  - Kim Y
FAU - Sun, Jong-Mu
AU  - Sun JM
FAU - Choi, Yoon La
AU  - Choi YL
FAU - Kim, Jhin Gook
AU  - Kim JG
FAU - Shim, Young-Mog
AU  - Shim YM
FAU - Park, Yeon Hee
AU  - Park YH
FAU - Ahn, Jin Seok
AU  - Ahn JS
FAU - Park, Keunchil
AU  - Park K
FAU - Han, Jung Ho
AU  - Han JH
FAU - Ahn, Myung-Ju
AU  - Ahn MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110528
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (KRAS protein, human)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Receptors, Fibroblast Growth Factor)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinoma/*genetics/pathology/surgery
MH  - Carcinoma, Non-Small-Cell Lung/genetics/pathology
MH  - ErbB Receptors/*genetics
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*genetics/pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - *Mutation
MH  - Polymerase Chain Reaction
MH  - Proto-Oncogene Proteins/*genetics
MH  - Proto-Oncogene Proteins c-met/*genetics
MH  - Proto-Oncogene Proteins p21(ras)
MH  - Rare Diseases/genetics
MH  - Receptors, Fibroblast Growth Factor/*genetics
MH  - Retrospective Studies
MH  - Sequence Analysis, DNA
MH  - ras Proteins/*genetics
PMC - PMC3133705
EDAT- 2011/06/01 06:00
MHDA- 2011/09/06 06:00
PMCR- 2011/05/28
CRDT- 2011/06/01 06:00
PHST- 2011/03/23 00:00 [received]
PHST- 2011/05/12 00:00 [accepted]
PHST- 2011/06/01 06:00 [entrez]
PHST- 2011/06/01 06:00 [pubmed]
PHST- 2011/09/06 06:00 [medline]
PHST- 2011/05/28 00:00 [pmc-release]
AID - 986 [pii]
AID - 10.1007/s00432-011-0986-0 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2011 Aug;137(8):1203-11. doi: 10.1007/s00432-011-0986-0. 
      Epub 2011 May 28.